Bydureon will fall even more in MD. Minds with Lilly drug

[Anonymous]

The non-inferiority result meets investor expectations, said Timothy Anderson, an analyst with Sanford C. Bernstein & Co. Other data from the full study, such as the drug’s effect on weight, will matter as well. “Dulaglutide should be well-positioned in the marketplace by virtue of attributes like its once-weekly dosing and its small needle size,” Anderson said in a note to clients, comparing it to Victoza’s daily dosing and Bydureon’s bigger needle.
http://bloom.bg/1hlisvs

 

[Anonymous]

The non-inferiority result meets investor expectations, said Timothy Anderson, an analyst with Sanford C. Bernstein & Co. Other data from the full study, such as the drug’s effect on weight, will matter as well. “Dulaglutide should be well-positioned in the marketplace by virtue of attributes like its once-weekly dosing and its small needle size,” Anderson said in a note to clients, comparing it to Victoza’s daily dosing and Bydureon’s bigger needle.
http://bloom.bg/1hlisvs

Yawn!!!

 

[Anonymous]

Say bye-bye to Bye! What a dog drug!

 

[Anonymous]

Yes. This is true. Bydureon did not could prove equal efficacy to Victoza, showed inferiority. Lilly's drug proved equal. PLUS Lilly already has experience selling not ony injectables but Byetta. Not that Lilly is even close to being the marketing genius that is NNI. Lilly certainly has the experience in this market that AZ lacks. In the end, Lilly will easily surpass the exenatide franchise that is co-founded.

 

[Anonymous]

You're giving Lilly and Lilly reps way too much credit. If the product does well, better than Bydureon, it's because it earned it. Not because Lilly earned it. Lilly is a crappy company with an unearned attitude.

 

[Anonymous]

http://www.fiercepharma.com/story/who-loses-most-lilly-vs-novo-diabetes-study-astrazeneca/2014-02-26

 

[Anonymous]

You're giving Lilly and Lilly reps way too much credit. If the product does well, better than Bydureon, it's because it earned it. Not because Lilly earned it. Lilly is a crappy company with an unearned attitude.

Lilly has been in diabetes forever, their injectable will make Bydureon a distant third, if that.

 

[Anonymous]

Lilly has been planning this a long time. They had their QW drug in development when they were partnering with Amylin selling Byetta. Lilly was also the company that was in charge of setting up the study of Bydureon vs Victoza. Lilly gets credits here either for a careful plan or a the benefactor of amcomedynof errors. Either way they will beat AZ in the GLP-1 market.